Your search
Results 103 resources
-
Summary. Recent work has offered competing explanations for the long-term evolution of corporate political action in the United States. In one, scholars have
-
Summary. Includes discussion of the limited utility of transparency for checking legal/institutional corruption.
-
Summary. Describes how commonly drug companies fail to adhere to obligations to disclose clinical trial results and how commonly they are willing to share clinical trial data. My collaboration with Dr. Miller is a direct result of my Safra fellowship.
-
Summary. This piece argues that, by framing individuals as the source of public health problems, nudging tends to serve the commercial interests of powerful corporate actors.
-
Summary. Describes how publicly disclosing drug company payments to physicians affects trust.
-
Summary. Describes the effects of publicly disclosing that physicians receive money from drug companies.
-
Summary. Describes gaps in the oversight of problematic faculty consulting relationships. This was my Safra project.
-
Summary. A review of which Brazilian voters think corruption is the most important issue facing the country and how that has changed over time.